Neurocrine Biosciences (NBIX) Share-based Compensation (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Share-based Compensation for 17 consecutive years, with $65.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 23.11% year-over-year to $65.0 million; the trailing twelve-month figure through Jun 2026 stood at $234.5 million (down 19.03% YoY), and the FY2025 full-year result was $217.9 million, down 19.77% from the prior year.
• Share-based Compensation rose to $65.0 million in Q2 2026 per NBIX's latest filing, from $57.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $142.5 million in Q4 2024 and bottomed at $37.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $54.8 million across 5 years, with a median of $48.6 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 219.51% in 2024, then plunged 58.88% in 2025.
• Over 5 years, Share-based Compensation stood at $43.5 million in 2022, then grew by 2.53% to $44.6 million in 2023, then surged by 219.51% to $142.5 million in 2024, then slumped by 58.88% to $58.6 million in 2025, then climbed by 10.92% to $65.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $65.0 million, $57.2 million, and $58.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.